NICE guidance on caplacizumab for treating acute acquired thrombotic thrombocytopenia purpura

Lancet Haematol. 2021 Jan;8(1):e14-e15. doi: 10.1016/S2352-3026(20)30406-3.

Authors

Mary Hughes¹, Carl Prescott¹, Nicole Elliott¹, Amanda I Adler²

Affiliations

¹ Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), Manchester M1 4BT, UK.
² Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), Manchester M1 4BT, UK; Oxford Centre for Diabetes Endocrinology and Metabolism, Oxford OX3 7LE, UK. Electronic address: amanda.adler@dtu.ox.ac.uk.

PMID: 33357475
DOI: 10.1016/S2352-3026(20)30406-3

No abstract available

Publication types

News

MeSH terms

Humans
Immunosuppressive Agents / therapeutic use
Plasma Exchange
Purpura, Thrombotic Thrombocytopenic / drug therapy
Purpura, Thrombotic Thrombocytopenic / pathology
Purpura, Thrombotic Thrombocytopenic / therapy*
Single-Domain Antibodies / immunology
Single-Domain Antibodies / therapeutic use*
Societies, Medical
von Willebrand Factor / immunology

Substances

Immunosuppressive Agents
Single-Domain Antibodies
von Willebrand Factor
caplacizumab

Supplementary concepts

Thrombotic thrombocytopenic purpura, acquired